Skip to main content

Tweets

Comparative study of 46 AOSD, 9 MAS & 31 adult HLH pts, shows that serum IL-18 was signif higher in AOSD than HLH (closely correlates w/ ferritin, sIL-2R). IL-18, sIL-2R, ‘arthralgia or arthritis’ independently distinguished AOSD from HLH https://t.co/ZW6e78nEkh

Dr. John Cush @RheumNow ( View Tweet )

4 years 9 months ago

Smoking worsens adult-onset Still’s disease. 185 AOSD pts, found 45 smokers who had higher risk of pericarditis (36 vs 16%), pleuritis (33 vs 14%), abd pain (18% vs 6%), higher systemic score (6.4 vs 5.4 ), More MAS (29% vs 6%), lung disease (18% vs 13%) https://t.co/ZKKhw1EbnD

Dr. John Cush @RheumNow ( View Tweet )

4 years 9 months ago
Decline in the incidence of Behcets Dz? Between 2004 to 2017 Korea has seen BD decreased from 8.15/100K (2004) to 1.51/100K (2017), an 81.5% decrease, greater for women and middle-aged people, but no change survival or mortality https://t.co/tvZSSGMOH7

Dr. John Cush @RheumNow ( View Tweet )

4 years 9 months ago
Congratulations to a great rheumatologist, Dr. Rita Jain, newly appointed Executive Vice President, Chief Medical Officer for ChemoCentryx, who's new C5a inhibitor avacopan (Tavneos) was just FDA approved for ANCA-assoc vasculitis! https://t.co/udhjSFF1Q0

Dr. John Cush @RheumNow ( View Tweet )

4 years 9 months ago
Cancer Risk in Systemic Lupus Erythematosus https://t.co/1pzSJn62MS https://t.co/Mm1F4HCNFs
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
A case of reactive arthritis following COVID-19 infection; manifest as dactylitis, psoriatic skin/nail lesions, painful oral & vaginal ulcers, subungual hyperkeratosis, but no oligoarthritis, or lumbar pain. https://t.co/nobMHGgKfZ

Dr. John Cush @RheumNow ( View Tweet )

4 years 9 months ago
A randomized controlled trial has shown that treatment of plaque psoriasis via costimulatory blockade ( CD28/B7) with abatacept did not prevent psoriasis relapse after withdrawal of ustekinumab. Read the full story on #RheumNow. https://t.co/8qgxYFW7EE https://t.co/8hi7JmR59a
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
NICE issued a positive final appraisal recommending upadacitinib in previously treated moderate active rheumatoid arthritis (RA). This will expand UPA use to nearly 27,000 RA patients in the UK. Final pub date is Nov 10, 2021 https://t.co/A8OuzNlrAz

Dr. John Cush @RheumNow ( View Tweet )

4 years 9 months ago
Could Auranofin work in COVID-19 infection? it may do so by inhibiting IL-6 production, as auranofin inhibits TLR3/TLR4, STAT3/JAK1 and thioredoxin reductase that regulates NF-kB (later IL-6); and may inhibit viral replication too. https://t.co/efLG4tzpTZ

Dr. John Cush @RheumNow ( View Tweet )

4 years 9 months ago

Catastrophic Still's dz occurs early; compares 20 AOSD w/ organ failure vs 40 AOSD without. CAT-AOSD had shorter Dz duration, earlier Rx need; risks: younger; splenomegaly, liver, cardiac,lung involvement; ferritin level, no arthralgia https://t.co/8WIMd0JxZr

Dr. John Cush @RheumNow ( View Tweet )

4 years 9 months ago
498 axSpA (62%M: 38% F): Compared to men, women had higher Dz activity, joint counts, enthesitis scores (all P ≤ 0.01), more pain, worse fatigue and Functional scores; all P < 0.05), less full time work, More DMARDs/pred, Depression & FM https://t.co/kPY9YDpA9J

Dr. John Cush @RheumNow ( View Tweet )

4 years 9 months ago
Costs of #JIA are substantial, total costs up to 44,832 USD annually. Direct costs up to $32,446 USD, accounting for 55-98 % of total. $$$ mostly related to meds; cost go up 3 fold after biologic initiation. (JIA Indirect costs are underrepresented) https://t.co/rukJPWqD0y

Dr. John Cush @RheumNow ( View Tweet )

4 years 9 months ago
×